Cell enrichment co BioCep raises NIS 2m

BioCep has developed a new method system for cell separation from the blood, making it possible to select 80-90% of the desired cells.

Cell enrichment start-up BioCep Ltd. has raised NIS 2 million. Max Herzberg led the round, and was joined by BioCep's parent company, technology incubator owner Capital Point Ltd. (TASE:CPTP).

BioCep has developed a new method system for cell separation from the blood, making it possible to select 80-90% of the desired cells. Current methods can extract only 20-30% from blood cells.

The company's Cell Enrichment Process (CEP) was invented by BioCep's chief scientist, Dr. Ofer Klein, and chief engineer, Mr. Aharon Lamish. Lamish, of Ziv Hospital in Safed, is an investor in the company, which operates out of the hospital.

BioCep is developing three products: a product to isolate fetus cells from maternal peripheral blood to replace prenatal tests, such as amniocentesis; a product to separate stem cells from blood cells; and a product to separate cancer cells from blood cells in order to monitor metastasis.

The company is also targeting the drug development and medical research markets.

Published by Globes [online], Israel business news - www.globes-online.com - on January 18, 2011

© Copyright of Globes Publisher Itonut (1983) Ltd. 2011

5 Comments
View comments in rows
Update by email about comments talkback
POST
Comments
Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018